We continue to be the 3rd largest generic pharmaceutical company by prescription volume in the U.S., reflecting our scale and market leadership.
Lupin’s purpose comes to life in its work across emerging markets. We focus on delivering accessible and high-quality healthcare solutions, adapting to the unique healthcare landscape in each of these markets.
Our market in India is a cornerstone of our global business, with a diversified portfolio across major therapy areas, including anti-TB, anti-diabetes, respiratory, and cardiology, among others.
The specialty business built by Lupin is anchored in science-led innovations across complex platforms, including a range of inhalation and injectable technologies.
Lupin's biosimilars business is focused on making complex biologics more accessible and affordable through in-depth research and quality-led manufacturing.
